PharmaTher Holdings Ltd (TSE:PHRM)
:PHRM
Want to see TSE:PHRM full AI Analyst Report?
PHRM Stock Chart & Stats
C$0.10
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.10
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.77
Previous CloseN/A
Volume18.00K
Average Volume (3M)158.34K
Market Cap
C$5.92M
Enterprise ValueC$5.12M
Total Cash (Recent Filing)C$1.04M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding91,019,066
10 Day Avg. Volume117,358
30 Day Avg. Volume158,340
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)16.46
Price to Sales (P/S)0.00
P/FCF Ratio-13.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt materially reduces financial distress risk and interest obligations, giving the company structural flexibility to prioritize R&D and clinical programs without near-term debt servicing. This durable balance-sheet strength lengthens optionality for strategic funding choices, though equity cushions remain thin.
Improving Cash BurnA materially improved burn rate versus the prior year indicates management has tightened cash usage and extended operational runway. Sustained lower burn, if maintained, reduces frequency and size of capital raises and supports continuity of clinical development, making funding needs more manageable over the medium term.
Narrowing LossesSteady reduction in net losses reflects improving cost control and operational discipline, increasing the chance of achieving positive operating leverage once revenue or milestone payments begin. Over months, this trend can conserve capital and improve investor confidence in management's execution of the development plan.
Bears Say
Pre-revenue Funding RiskBeing pre-revenue with persistent negative operating and free cash flow means the company structurally relies on external financing to continue R&D and trials. Over the medium term this creates dilution and execution risk: failure to secure timely funding could delay programs or force unfavorable financing, impairing long-term value creation.
Eroding Equity BaseA sharply reduced equity cushion limits the company's ability to absorb further losses or fund setbacks without diluting shareholders. Structurally, a thin equity base constrains strategic options—making partnerships, licensing, or debt-free scaling more difficult and increasing solvency risk if clinical timelines slip.
Weak Cash GenerationNegative and volatile cash generation demonstrates the company cannot self-fund development and remains exposed to capital markets. Over several months this undermines planning certainty for multi-stage trials, raises the probability of disruptive financings, and slows progress toward commercialization absent durable revenue or milestone inflows.
PharmaTher Holdings Ltd News
PHRM FAQ
What was PharmaTher Holdings Ltd’s price range in the past 12 months?
PharmaTher Holdings Ltd lowest stock price was C$0.06 and its highest was C$0.77 in the past 12 months.
What is PharmaTher Holdings Ltd’s market cap?
PharmaTher Holdings Ltd’s market cap is C$5.92M.
When is PharmaTher Holdings Ltd’s upcoming earnings report date?
PharmaTher Holdings Ltd’s upcoming earnings report date is Sep 24, 2026 which is in 129 days.
How were PharmaTher Holdings Ltd’s earnings last quarter?
PharmaTher Holdings Ltd released its earnings results on Jan 30, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is PharmaTher Holdings Ltd overvalued?
According to Wall Street analysts PharmaTher Holdings Ltd’s price is currently Overvalued.
Does PharmaTher Holdings Ltd pay dividends?
PharmaTher Holdings Ltd does not currently pay dividends.
What is PharmaTher Holdings Ltd’s EPS estimate?
PharmaTher Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaTher Holdings Ltd have?
PharmaTher Holdings Ltd has 91,019,066 shares outstanding.
What happened to PharmaTher Holdings Ltd’s price movement after its last earnings report?
PharmaTher Holdings Ltd reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PharmaTher Holdings Ltd?
Currently, no hedge funds are holding shares in TSE:PHRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaTher Holdings Ltd
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
Technical Analysis
COSCIENS Biopharma
―
Kane Biotech
―
BetterLife Pharma
―
BioVaxys Technology
―
Marvel Biosciences Corp
―
Options Prices
Currently, No data available
---